8 completed, 4 recruiting, 2 terminated, 1 active not recruiting. 18 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Completed 8, Recruiting 4, Terminated 2, Active not recruiting 1, Not yet recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow Placebo IV: new trials by email Literature Review of Placebo IV trials Research Report on Placebo IV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Efficacy and Safety of Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4- Congenital Myasthenic Syndromes (CMS) Adimanebart IV, Placebo IV - Congenital Myasthenic Syndrome, CMS | Phase 3 | Not yet recruiting | argenx | 105 | 2026-09-01 | 2026-10-19 |
| A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP) Efgartigimod IV, Placebo IV - Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia | Phase 2 / Phase 3 | Recruiting | argenx | 24 | 2025-10-20 | 2026-10-16 |
| A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP Empasiprubart IV, Placebo IV - Chronic Inflammatory Demyelinating Polyneuropathy, CIDP | Phase 3 | Recruiting | argenx | 160 | 2025-09-16 | 2026-10-27 |
| A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia Efgartigimod IV, Placebo IV - Primary Immune Thrombocytopenia (ITP) | Phase 3 | Recruiting | argenx | 69 | 2024-10-18 | 2026-05-01 |
| A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis Efgartigimod IV, Placebo IV - Generalized Myasthenia Gravis, gMG | Phase 3 | Active not recruiting | argenx | 119 | 2024-04-16 | 2026-08-10 |
| Enantyum® IV Versus Piroxen® IM in Emergency Pain Management Dexketoprofen, Piroxicam - Traumatic Injury | Phase 3 | Unknown | Riadh Boukef | 300 | 2023-07-15 | 2024-05-08 |
| Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study Toripalimab, Lenvatinib mesylate capsules, Placebo IV - Intrahepatic Cholangiocarcinoma | Phase 3 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 480 | 2023-06-19 | 2025-04-23 |
| A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis Mirikizumab IV, Mirikizumab SC, Vedolizumab IV - Ulcerative Colitis | Phase 3 | Withdrawn | Eli Lilly and Company | 2021-04-20 | 2021-05-06 | |
| A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments Ustekinumab 6 mg/kg, Ustekinumab 90 mg, Placebo IV - Polymyositis, Dermatomyositis | Phase 3 | Terminated | Janssen Pharmaceutical K.K. | 51 | 2019-07-26 | 2025-04-29 |
| A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion Alteplase, acetylsalicylic acid, Placebo Oral Tablet - Central Retinal Artery Occlusion | Phase 3 | Completed | Nantes University Hospital | 70 | 2018-06-08 | 2024-01-24 |
| Maxigesic IV Phase 3 Bunionectomy Study Maxigesic IV, IV Acetaminophen, IV Ibuprofen - Post Operative Pain | Phase 3 | Completed | AFT Pharmaceuticals, Ltd. | 276 | 2016-10-26 | 2021-07-06 |
| Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis Vedolizumab 300 mg IV, Placebo IV, Vedolizumab 108 mg SC - Colitis, Ulcerative | Phase 3 | Completed | Takeda | 383 | 2015-12-18 | 2022-05-25 |
| A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery CR845 IV 1 mcg/kg, CR845 IV 0.5 mcg/kg, Placebo IV - Post Abdominal Surgery Pain | Phase 2 / Phase 3 | Completed | Cara Therapeutics, Inc. | 451 | 2015-09-01 | 2019-05-31 |
| A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis Placebo IV, Placebo SC, Ustekinumab IV - Colitis, Ulcerative, Inflammatory Bowel Diseases | Phase 3 | Completed | Janssen Research & Development, LLC | 961 | 2015-07-10 | 2025-04-29 |
| A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors Denosumab 70 mg/mL, Zoledronic acid 4 mg, Placebo IV - Fractures, Bone | Phase 3 | Completed | GlaxoSmithKline | 487 | 2013-08-01 | 2017-01-16 |
| A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI) Placebo SC, Placebo IV, Ustekinumab 90 mg SC q8w - Crohn's Disease, Colitis | Phase 3 | Completed | Janssen Research & Development, LLC | 1282 | 2011-09-13 | 2025-02-04 |
| Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study Placebo IV, Placebo SC, Tanezumab SC - Osteoarthritis, Arthritis | Phase 3 | Terminated | Pfizer | 385 | 2010-03-30 | 2021-05-05 |
| Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA) Golimumab 50 mg SC, Golimumab 2 mg/kg IV, Methotrexate (MTX) - Arthritis, Arthritis, Rheumatoid | Phase 3 | Completed | Janssen Biotech, Inc. | 433 | 2009-12-01 | 2015-04-30 |
Colitis, Ulcerative (3) · Arthritis (2) · Inflammatory Bowel Diseases (2) · Purpura, Thrombocytopenic, Idiopathic (2) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Cholangiocarcinoma (1) · Colitis (1) · Crohn Disease (1) · Dermatomyositis (1) · Fractures, Bone (1) · Myasthenia Gravis (1) · Myasthenic Syndromes, Congenital (1) · Osteoarthritis (1) · Pain (1)
argenx (5) · Janssen Research & Development, LLC (2) · AFT Pharmaceuticals, Ltd. (1) · Cara Therapeutics, Inc. (1) · Eli Lilly and Company (1) · GlaxoSmithKline (1) · Janssen Biotech, Inc. (1) · Janssen Pharmaceutical K.K. (1) · Nantes University Hospital (1) · Pfizer (1) · Riadh Boukef (1) · Shanghai Junshi Bioscience Co., Ltd. (1) · Takeda (1)
United States (10) · United Kingdom (8) · France (7) · Germany (7) · Poland (7) · Czechia (6) · Hungary (6) · Japan (6) · Romania (6) · Serbia (6) · Austria (5) · Belgium (5) · Bulgaria (5) · Canada (5) · China (5)
Joseph Stauffer, DO, MBA (1) · Stephen E Daniels, DO (1)
PMID 32964215, PMID 38310565, PMID 27959607, PMID 28035867, PMID 29142515, PMID 29409871, PMID 29427176, PMID 29797519, PMID 29909019, PMID 30739254, PMID 30936738, PMID 31158271, PMID 31279870, PMID 31447129, PMID 31470005, PMID 31553833, PMID 32806876, PMID 32853634, PMID 33086438, PMID 33618023, PMID 33973384, PMID 34077627, PMID 34499349, PMID 34626502, PMID 35276329, PMID 36150926, PMID 37368103, PMID 37391056, PMID 37460782, PMID 37652554, PMID 38025971, PMID 38095692, PMID 38417060, PMID 39368474, PMID 39614619, PMID 40357993, PMID 40668079, PMID 41109232, PMID 42427284
2025 (3), 2009 (1), 2014 (1), 2015 (1), 2019 (1)